Risk Factors in Coronary Heart Disease

Article1 November 1964Risk Factors in Coronary Heart DiseaseThe Framingham StudyWILLIAM B. KANNEL, M.D., F.A.C.P., THOMAS R. DAWBER, M.D., F.A.C.P., GARY D. FRIEDMAN, M.D., WILLIAM E. GLENNON, M.S., PATRICIA M. MCNAMARAWILLIAM B. KANNEL, M.D., F.A.C.P.Search for more papers by this author, THOMAS R. DAWBER, M.D., F.A.C.P.Search for more papers by this author, GARY D. FRIEDMAN, M.D.Search for more papers by this author, WILLIAM E. GLENNON, M.S.Search for more papers by this author, PATRICIA M. MCNAMARASearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-61-5-888 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAt Framingham, Massachusetts, the National Heart Institute has been following 5,127 men and women aged 30 to 60 years in a study of factors related to the development of coronary heart disease (CHD) and hypertension. Data for a decade of follow-up studies of this population are available for analysis.From a study of those who have developed disease under observation in comparison to those who have remained free of the disease, factors of risk and susceptible individuals have been identified. The factors associated with excess risk that have been identified are: serum cholesterol level, blood pressure, cigarette smoking, vital capacity,...References1. GORDONMOORESHURTLEFFDAWBER TFEDTR: Some methodologic problems in the long-term study of cardiovascular disease: observations on the Framingham Study. J. Chron. Dis. 10: 186, 1959. CrossrefGoogle Scholar2. KANNELDAWBERKAGANREVOTSKIESTOKES WBTRANJ: Factors of risk in the development of coronary heart disease—six-year follow-up experience: The Framingham Study. Ann. Intern. Med. 55: 33, 1961. LinkGoogle Scholar3. KAHN HA: A method for analyzing longitudinal observations on individuals in the Framingham Heart Study. Proceedings of the Social Statistics Section of the American Statistical Association, 1961. Google Scholar4. DELALLAGOFMAN OFJW: Ultracentrifugal analysis of serum lipoprotein, in Methods of Biochemical Analysis, vol. 1, edited by GLICK, D., Interscience, New York, 1954, pp. 459-478. Google Scholar5. ABELLLEVYBRODIEKENDALL LLBBBBFE: A simplified method for estimation of total cholesterol in serum and demonstration of its specificity. J. Biol. Chem. 195: 357, 1952. CrossrefMedlineGoogle Scholar6. YOUNGBURGYOUNGBURG GEMV: Phosphorus metabolism; system of blood phosphorus analysis. J. Lab. Clin. Med. 16: 158, 1930. Google Scholar7. FISKESUBARROW CHY: The colorimetric determination of phosphorus. J. Biol. Chem. 66: 375, 1925. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Framingham, MassachusettsFrom the Heart Disease Epidemiology Study, Framingham, Mass., and the National Heart Institute, National Institutes of Health, U. S. Public Health Service, Bethesda, Md.Requests for reprints should be addressed to William B. Kannel, M.D., Heart Disease Epidemiology Study, Dept. of Health, Education, and Welfare, 25 Evergreen St., Framingham, Mass. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByLEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery DiseaseEfficacy of dulaglutide on vascular health indexes in subjects with type 2 diabetes: a randomized trialGenetic Determinants of Plasma Low-Density Lipoprotein Cholesterol Levels: Monogenicity, Polygenicity, and “Missing” HeritabilityGesättigte Fettsäuren und kardiovaskuläres RisikoThe burden of cholesterol accumulation through the lifespan: why pharmacological intervention should start earlier to go further?Is a High HDL-Cholesterol Level Always Beneficial?Milk fat: opportunities, challenges and innovationRisk and protective factors for intuitive and rational judgment of cybersecurity risks in a large sample of K-12 students and teachersLong-term exposure to ambient air pollution is associated with coronary artery calcification among asymptomatic adultsADAM17 Boosts Cholesterol Efflux and Downstream Effects of High-Density Lipoprotein on Inflammatory Pathways in MacrophagesRapid Decrease in HDL-C in the Puberty Period of Boys Associated with an Elevation of Blood Pressure and Dyslipidemia in Korean Teenagers: An Explanation of Why and When Men Have Lower HDL-C Levels Than WomenCeramide Scores Predict Cardiovascular Risk in the CommunityIntegrating lipidomics and genomics: emerging tools to understand cardiovascular diseasesRelationship between lipoproteins, thrombosis, and atrial fibrillationImpact of Blood Pressure Visit‐to‐Visit Variability on Adverse Events in Patients With Nonvalvular Atrial Fibrillation: Subanalysis of the J‐RHYTHM RegistryHow ApoB Measurements Could Improve Prevention of Cardiovascular DiseaseHDL-C and Cardiovascular Risk: You Don't Need to Worry about Extremely High HDL-C LevelsPravastatin‐induced changes in expression of long non‐coding and coding RNAs in endothelial cellsGut microbiota and cardiovascular disease: opportunities and challengesObesity-Related Changes in High-Density Lipoprotein Metabolism and FunctionLipoproteins-Nanocarriers as a Promising Approach for Targeting Liver Cancer: Present Status and Application ProspectsIcosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterolComparison of different algorithms for the assessment of cardiovascular risk after kidney transplantation by the time of entering waiting listA Review of Lipidomics of Cardiovascular Disease Highlights the Importance of Isolating LipoproteinsHigh-Density Lipoproteins and Apolipoprotein A1A Compendium of the Biological Effects of Apolipoprotein A-I MilanoLDL como objetivo terapéuticoAssociation between high-density lipoprotein cholesterol and all-cause mortality in the general population of northern ChinaSocioeconomic status and education level are associated with dyslipidemia in adults not taking lipid-lowering medication: a population-based studyRare P376L variant in the SR-BI gene associates with HDL dysfunction and risk of cardiovascular diseaseRounding the corner on residual risk: Implications of REDUCE‐IT for omega‐3 polyunsaturated fatty acids treatment in secondary prevention of atherosclerotic cardiovascular diseaseLipid-lowering agents for the treatment of hyperlipidemia in patients with chronic kidney disease and end-stage renal disease on dialysis: a reviewUteroplacental Insufficiency Impairs Cholesterol Elimination in Adult Female Growth-Restricted Rat Offspring Fed a High-Fat DietMyocardial Infarction—From Atherosclerosis to ThrombosisCurrent pharmacotherapeutic options for primary dyslipidemia in adultsHDL Cholesterol as a Marker of Disease Severity and Prognosis in Patients with Pulmonary Arterial HypertensionGenome-wide association analysis of HDL-C in a Lebanese cohortCholesterol and Atherosclerotic Cardiovascular Disease: A Lifelong ProblemRisk Factor Variability and Cardiovascular OutcomeAllele-specific enhancers mediate associations between LCAT and ABCA1 polymorphisms and HDL metabolismThe Effects of a Physically Active Lifestyle on the Health of Former Professional Football PlayersMetabolomics and Heart Diseases: From Basic to Clinical ApproachAtherosclerosisIdentification of the first Tangier disease patient in Lebanon carrying a new pathogenic variant in ABCA1Structural Basis and Functional Mechanism of Lipoprotein in Cholesterol TransportUnravelling HDL—Looking beyond the Cholesterol Surface to the Quality WithinEfficacy and Safety of Ezetimibe and Rosuvastatin Combination Therapy Versus Those of Rosuvastatin Monotherapy in Patients With Primary HypercholesterolemiaAPPROACHES TO STATIN THERAPY ADHERENCE IMPROVEMENTClinical and pathophysiological evidence supporting the safety of extremely low LDL levels—The zero-LDL hypothesisLipoproteins for therapeutic delivery: recent advances and future opportunitiesLipoprotein in cholesterol transport: Highlights and recent insights into its structural basis and functional mechanismHDL Cholesterol Metabolism and the Risk of CHD: New Insights from Human GeneticsAssociation between High-density-lipoprotein-cholesterol Levels and the Prevalence of Asymptomatic Intracranial Arterial StenosisHistory of lipidology and lipoprotein apheresisCholesterol and Lipoprotein Metabolism and Atherosclerosis: Recent Advances in Reverse Cholesterol TransportTime to ditch HDL-C as a measure of HDL function?The Role of Omega-3 Fatty Acids in Reverse Cholesterol Transport: A ReviewAdvances in the management of dyslipidemiaPrevalence of Elevated Cardiovascular Risks in Young Adults: A Cross-sectional Analysis of National Health and Nutrition Examination SurveysKrishna K. Patel, MD, Glen B. Taksler, PhD, Bo Hu, PhD, and Michael B. Rothberg, MD, MPHHDL and macrophages: explaining the clinical failures and advancing HDL-based therapeutics in cardiovascular diseases?Potential and Caveats of Lipidomics for Cardiovascular DiseaseHigh-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular ConditionsHypercholesterinämie – Wo stehen wir heute? Wo wollen wir hin?Translational and Therapeutic Approaches to the Understanding and Treatment of DyslipidemiaImmunogenicity, Inflammation, and Lipid Accumulation in Cynomolgus Monkeys Infused with a Lipidated Tetranectin-ApoA-I Fusion ProteinNew Therapeutic Approaches to the Treatment of DyslipidemiaCausal Inference in Medicine via Mendelian RandomizationComparison of Adherence to Guideline-Based Cholesterol Treatment Goals in Men Versus WomenHDL-cholesterol and cardiovascular diseaseVariability in Low-Density Lipoprotein Cholesterol and Cardiovascular RiskHDL re-examinedThe role of T and B cells in human atherosclerosis and atherothrombosisHeart health: diets and lifestyleCholesterol ScreeningThe evidence base for fat guidelines: a balanced dietCardiac BiomarkersZebrafish as a model for apolipoprotein biology: comprehensive expression analysis and a role for ApoA-IV in regulating food intakeLxr-driven enterocyte lipid droplet formation delays transport of ingested lipidsHDL and cardiovascular diseaseHDL inhibits the effects of oxidized phospholipids on endothelial cell gene expression via multiple mechanismsOur obsession with saturated fats: is it time to rethink their role in the coronary artery disease?HDL Hypothesis: Where Do We Stand Now?Lipoprotein Subclasses and Cardiovascular Disease Risk in Insulin-Resistant DiabetesMR Imaging in Population-Based ResearchPretransplant dyslipidaemia determines outcome in lung transplant recipientsKorrektsiya dislipidemiy pri soputstvuyushchey arterial'noy gipertonii s pozitsiy obnovlennoy paradigmy serdechno-sosudistogo riskaRelationship of low- and high-density lipoproteins to coronary artery plaque composition by CT angiographyAtherosclerotic Heart DiseaseVascular disease and dementias: Paradigm shifts to drive research in new directionsPolyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and miceAbdominal Obesity and Cardiovascular Disease: Is Inflammation the Missing Link?Mortalité coronarienne élevée à l’Île Maurice. Étude des facteurs de risque et analyses génomiquesMethods for Studying Rodent Intestinal Lipoprotein Production and MetabolismVisceral adiposity as a target for the management of the metabolic syndromeLipid Lowering in Coronary Artery DiseaseHypertriglyceridemic waist: missing piece of the global cardiovascular risk assessment puzzle?Improving lipid profiles and increasing use of lipid-lowering therapy in England: results from a national cross-sectional survey - 2006Clinical experience with rosuvastatin in the management of hyperlipidemia and the reduction of cardiovascular riskInformativeness of indices of blood pressure, obesity and serum lipids in relation to ischaemic heart disease mortality: the HUNT-II studyLipid parameters for measuring risk of cardiovascular diseaseThe Multiconstituent Cardiovascular Pill (MCCP): Challenges and Promises of Population Based Prophylactic Drug Therapy for Heart Attack Prevention and EradicationStroke: A Modern HistoryLayperson-Oriented versus Clinical-Based Models for Assessing 10-Year Incidence of Coronary Heart Disease: National FINRISK StudyThe Contribution of the Framingham Heart Study to the Prevention of Cardiovascular Disease: A Global PerspectiveStatins and inflammation: an updateStatin Effects on Both Low-Density Lipoproteins and High-Density Lipoproteins: Is There a Dual Benefit?Determinanten van ziekte en gezondheid op hoge leeftijd:Relation of Corneal Arcus to Cardiovascular Disease (from the Framingham Heart Study Data Set)Habitual consumption of eggs does not alter the beneficial effects of endurance training on plasma lipids and lipoprotein metabolism in untrained men and womenPhysicochemical basis of the digestion and absorption of triacylglycerolA Novel Clinical Entity: Triglyceride Deposit Cardiomyovasculopathy Implications and Perspectives from ''Obesity of the Heart''Smoking and smoking cessation—The relationship between cardiovascular disease and lipoprotein metabolism: A reviewAbdominal obesity: The cholesterol of the 21st century?Review Paper: Pathophysiology of Myocardial Reperfusion Injury: The Role of Genetically Engineered Mouse ModelsMorbidité et mortalité à 10 ans d’une cohorte de patients dyslipidémiques ayant consulté en centre hospitalierInfluencer la recherche pharmaceutique : un enjeu pour la connaissance des pathologiesAcute Myocardial Infarction and Acute Coronary Syndrome: Then and Now (1950-2005)Update on lipid-lowering therapy and LDL-cholesterol targetsSmoking, Heart Disease, and Lipoprotein MetabolismCalculating global risk: the key to interventionStatus of lipid-lowering therapy prescribedbased on recommendations in the 2002 report of the Japan Atherosclerosis Society Guideline for Diagnosis and Treatment of Hyperlipidemia in Japanese Adults: A study of the Japan Lipid Assessment Program (J-LAP)Omega-6 fatty acids and coronary artery disease: The pros and consTotal Cholesterol and Mortality in China, Poland, Russia, and the USEffectiveness of simvastatin therapy in raising HDL-C in patients with type 2 diabetes and low HDL-CThe effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart diseaseEffects of Saengshik Supplementation on Health Improvement in Diet-Induced Hypercholesterolemic RatsTriglycerides, High-Density Lipoprotein Cholesterol, and Risk of Ischemic Heart Disease: A View from the Copenhagen Male StudyFrom interaction of lipidic vehicles with intestinal epithelial cell membranes to the formation and secretion of chylomicronsMaking practical sense of clinical trial data in decreasing cardiovascular riskEffect of the Angiotensin II Receptor Antagonist Valsartan on Lipid Profile and Glucose Metabolism in Patients with HypertensionEgg Consumption and Coronary Heart Disease: An Epidemiologic OverviewEffect of felodipine on the serum lipid profile of patients with hypertensionComment on Issues in the Assessment of Physical Activity in WomenLipid Lowering TherapyVino y corazónSynthesis of triphosphonate analogues of farnesyl pyrophosphate. Inhibitors of squalene synthase and protein:farnesyl transferaseLong-term Treatment With Pravastatin Alone and in Combination With Gemfibrozil in Familial Type IIB Hyperlipoproteinemia or Combined HyperlipidemiaHypercholesterolemia in the United States: How far have we come?Insulin resistance in essential hypertensive patients with impaired glucose toleranceLong-term treatment with simvastatin in patients with familial combined hyperlipidemiaLong-term metabolic effects of antihypertensive drugsLow-dose (5 mg) simvastatin versus gemfibrozil in the treatment of primary moderate hypercholesterolemia: Results of a belgian multicenter studyAntihypertensive and Antihyperlipidemic Effects of FunoranDoes Gallopamil Modify Blood Lipids?The Place of Alpha Blockers in the Antihypertensive ArmamentariumComparative trial of doxazosin and atenolol on cardiovascular risk reduction in systemic hypertensionEffects on Plasma Lipids during Long Term Antihypertensive Treatment with FelodipineHigh density lipoprotein cholesterol and total cholesterol in children with asthma and allergic rhinitisLipids and fatty acids and their relationship to restenosisVariability in Cholesterol Measurements in a Worksite Cholesterol Screening ProgramAngiographic Evolution of Coronary Atherosclerosis in Patients Receiving PropranololEffects of long-term verapamil therapy on serum lipids and other metabolic parametersUltrasound as Used in the Framingham Hearl StudyEstrogen replacement and cardiovascular disease: Serum lipids and blood pressure effectsManagement of blood lipid abnormalities in coronary heart disease patientsThe cholesterol controversy is over. Why did it take so long?Measurement of selected cardiovascular risk factors in childrenApolipoprotein, low density lipoprotein subfraction, and insulin associations with familial combined hyperlipidemia. Study of Utah patients with familial dyslipidemic hypertension.Lovastatin in the Treatment of Multifactorial Hyperlipidemia Associated With ProteinuriaCan Risk Scores for Vascular Disease in Gout Patients be Improved?Nutritional requirements of the agedSerum lipids and lipoproteins after myocardial infarction: Associations with cardiovascular mortality and experience in the Aspirin Myocardial Infarction StudyBeta-Blocking Agents and Plasma Lipids: An UpdateGeographical distribution of cerebrovascular disease mortality and food intakes in JapanTreatment of the Hyperlipidemia of the Nephrotic Syndrome: A Controlled TrialSerum apolipoproteins AI and B and lipoproteins in middle aged men with and without previous myocardial infarction.Plasma triglycerides related decrease in high-density lipoprotein cholesterol and its association with myocardial infarction in heterozygous familial hypercholesterolemiaNutritional Value of LipidsPathogenesis of Coronary Atherosclerosis: Prevention of AtherogenesisEffect of Brazilin on Plasma Lipid Levels in Spontaneously Hypertensive RatsEND-ORGAN RESPONSES TO THYROXINE THERAPY IN SUBCLINICAL HYPOTHYROIDISMRenal handling of plasma high density lipoproteinEffects of Red ginseng-crude saponin on plasma lipid levels in rats fed on a diet high in cholesterol and triglycerideMetabolic disturbances increasing the risk of coronary heart disease during diuretic-based antihypertensive therapy: Lipid alterations and glucose intoleranceEffect of trimazosin on serum lipid profiles in hypertensive patientsSome wrong-way chemical changes during antihypertensive treatment: Comparison of indapamide and related agentsEarly indicators for the risk of atherogenesis a field test of a new methodology on kindergarten children in DüsseldorfRisk factors for pulmonary embolismHypolipidemic activity and studies of a mortality in patients with and in their blood serum in of plasma and smoking data and cardiovascular fatty composition of in a study of coronary heart disease risk of serum triglycerides and high density lipoprotein cholesterol in of Gemfibrozil on Serum Lipids in und of time in asymptomatic patients with primary Effects of Some for of The National Study A Controlled Trial of and J. M.D., M. M.D., M.D., M.D., M.D., M.D., M.D., M.D., M.D., M.D., M.D., D. M.D., M.D., B. M.D., of apolipoprotein B and and cholesterol as risk factors in the development of coronary artery disease in patients by an Cholesterol und in Serum und of lipids and lipoprotein in The IN effect of cholesterol and on the lipid content in of Heart Health A Review of the and health of high students with to heart disease risk Lipoproteins in the to of Human Serum Lipids of and Cardiovascular of high density lipoprotein and serum cholesterol levels in a and an effects of a and diet on plasma and of the familial on plasma lipid and Lipoproteins in and and with and composition of human serum lipoproteins and cholesterol metabolism in the trial in the primary prevention of ischaemic heart disease from the of of blood lipids and blood in the effect of on plasma and its by a in antihypertensive the of the of serum lipid determination in and of atherosclerotic artery in the of on of and lipid levels in a density lipoproteins in ischaemic heart and heart und of Lipid Metabolism in Patients With lipid profiles in patients of myocardial infarction in the practical management of of plasma to plasma lipids and lipoproteins in subjects with vascular IN in human coronary and the of blood pressure and plasma cholesterol in in and the Role of Drug on with to the Serum Lipid of and Therapy on Serum in Human Atherosclerotic of serum lipids by of in IN and serum lipoprotein heart disease risk factors in The lipid and lipoprotein during in IN in Asymptomatic Primary in Patients with and Coronary With Review of the Metabolism in Lipid Levels and Therapy of of type as a in coronary artery of diet on and intestinal in and of Lipids in the of The Framingham of plasma lipids and lipoprotein to atherosclerosis and studies of coronary heart disease and in Japanese men in and and of on lipid transport in and Coronary heart disease as a prevention through of plasma cholesterol in cholesterol and levels in human from and New IN A and in of Physical in Male Patients after Myocardial of and to of Serum Lipoproteins in Myocardial in patients with coronary heart diseaseThe of Coronary and the to in Asymptomatic and vascular of the Plasma und of the in from the of Serum Cholesterol and Mortality in disease and of serum lipids in role of insulin in different und IN between Serum Lipid and Risk Factors in Myocardial of Changes in Clinical to and in the and Coronary Heart of Plasma Lipoprotein in a Population of the of Heart The Framingham StudyThe of plasma blood and serum lipid abnormalities in patients with atherosclerotic diseaseThe Coronary IN blood pressure and the of atherosclerosis in a population of A in the of atherosclerotic versus blood pressure and risk of coronary heart lipid of coronary heart IN Treatment of IN Cholesterol, and the Risk of Coronary Heart Disease The Framingham StudyWILLIAM B. KANNEL, M.D., WILLIAM M.D., PATRICIA M. of lipid en la Disease and and of coronary of myocardial and Cardiovascular study of the primary prevention of coronary heart in Atherosclerosis: and Drug Ischemic Heart Disease, and M.D., M. M.D., M.D., J. of the of Heart Disease: by the Framingham IN Type Effects of and abnormalities in patients with coronary artery basis of human Pressure and Risk of Coronary Heart Disease: The Framingham in the and IN Serum Triglyceride and Cholesterol Levels heart disease in of and in Young Patients with Coronary Heart of heart changes in chronic IN Heart Disease: Screening by Familial and Coronary Artery D. in Human Atherosclerosis With Therapeutic M.D., A IN of serum lipids and of lipoprotein in myocardial Lipids in Infarction American M.D., of atherosclerotic in and Atherosclerotic Vascular and Lipid in Patients with Coronary Heart M.D., M.D., J. M.D., of on serum fat in atherosclerotic in the clinical analysis of coronary lipoprotein levels in a New population prevention of coronary heart disease by clinical of coronary A Nutrition and Atherosclerotic in prevention of coronary heart Disease, and of on the of Diagnosis of Heart in with Blood Serum and development of coronary heart disease in relation to of cholesterol in the Study of Coronary Heart Disease in Young of fat in relation to in assessment of the of the in the of cardiovascular to M.D., F.A.C.P., M.D., M.D., Advances in of Coronary Artery Mechanism and Prevention by November heart heart risk and health November PDF